

# Christoph Kapitza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7037194/publications.pdf>

Version: 2024-02-01

19  
papers

815  
citations

840119

11  
h-index

839053

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

886  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus <sc>H</sc>umalogÂ® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test earlyâ€phase study. Diabetes, Obesity and Metabolism, 2022, 24, 187-195.   | 2.2 | 6         |
| 2  | Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 684-692.  | 2.2 | 6         |
| 3  | Acute effects of linagliptin on intact and total glucagonâ€like peptideâ€1 and gastric inhibitory polypeptide levels in insulinâ€dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes, Obesity and Metabolism, 2022, 24, 806-815.   | 2.2 | 0         |
| 4  | A singleâ€dose euglycaemic clamp study in two cohorts to compare the exposure of <sc>SAR341402</sc> (insulin aspart) Mix 70/30 with <sc>US</sc>â€and <sc>Europeanâ€</sc>approved versions of insulin aspart Mix 70/30 and <sc>SAR341402</sc> rapidâ€acting solution in subjects with type 1 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 674-681. | 2.2 | 4         |
| 5  | Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with shortâ€and longâ€acting glucagonâ€like peptideâ€1 receptor agonists in type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2344-2353.  | 2.2 | 8         |
| 6  | Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 278-284.   | 2.4 | 12        |
| 7  | Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on mealâ€related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 599-611.   | 2.2 | 10        |
| 8  | Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 2137-2145.   | 4.3 | 21        |
| 9  | Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, Obesity and Metabolism, 2020, 22, 1789-1798.   | 2.2 | 49        |
| 10 | Impact of insulin glargine and lixisenatide on Î²â€cell function in patients with type 2 diabetes mellitus: <sc>A</sc> randomized openâ€label study. Diabetes, Obesity and Metabolism, 2017, 19, 1625-1629.  | 2.2 | 9         |
| 11 | Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia, 2017, 60, 1390-1399.  | 2.9 | 68        |
| 12 | Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 622-627.   | 2.2 | 24        |
| 13 | Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixedâ€ratio combination therapy. Journal of Clinical Pharmacology, 2015, 55, 1369-1377.   | 1.0 | 24        |
| 14 | Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. Diabetes Care, 2015, 38, 1263-1273.  | 4.3 | 216       |
| 15 | Semaglutide, a onceâ€weekly human GLPâ€1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology, 2015, 55, 497-504.   | 1.0 | 117       |
| 16 | Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 97, 258-266.  | 1.1 | 135       |
| 17 | The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Advances in Therapy, 2011, 28, 213-226.  | 1.3 | 67        |
| 18 | The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Advances in Therapy, 2011, 28, 650-660.  | 1.3 | 27        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 951-955. | 1.0 | 12        |